Compare Abeona Therapeutics Inc (ABEO) vs Fox Corp Class B (FOX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Fox Corp Class B — how do they compare? Abeona Therapeutics Inc trades at $7.51 (market cap $421.19M), while Fox Corp Class B trades at $55.78 (market cap $24.58B). The key difference: Fox Corp Class B is far larger — about 58.4× Abeona Therapeutics Inc's market cap, and Fox Corp Class B pays a 1.05% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | FOX | |
|---|---|---|
Market Cap | $421.19M | $24.58B |
Sector | Health | Media |
52-Week High | $7.45 | $67.76 |
52-Week Low | $4.17 | $44.39 |
Enterprise Value | $276.10M | $27.94B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
FOX trades at $55.32, down 1.79% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate, and revenue growth to $16.30 billion in 2025. A dividend of $0.29 is scheduled for September 2026, reflecting financial health. Analyst sentiment is mixed but leans positive, with 42.86% recommending buy.
The outlook for FOX is favorable, driven by digital growth and advertising momentum, though risks include competitive pressures and potential economic volatility. The stock's valuation metrics, including a P/E of 14.41, suggest reasonable pricing relative to earnings, supporting a cautious optimism for investors seeking exposure to media and entertainment sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →
